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Purpose:  Radiotherapy retreatment (radical or palliative) is 
useful in selected patients. Two recent publications provided 
methods for estimating changes in spinal radio-tolerance with 
time between initial radiotherapy and retreatment, but with 
important limitations.    
Materials and methods: A model was developed to find a 
temporal relationship between the percentages of the 
tolerance biological effective doses (%BED) for two treatment 
courses. The primate data of Ang et al (2010), isoeffective 
for a 10% incidence of myelitis, with re-treatment intervals 
of 1, 2 and 3 years provided the fitting parameters. As 
summarised in Jones and Hopewell (2014), rodent studies 
used shorter intervals (~ 6 months), spinal tissue recovery 
starts around 70 days after first treatment courses, and 
appears dose related (experiments showed little or no 
recovery six months after initial low dose treatments around 
20-30% of %BED tolerance).  
Thus recovery displays different time scales contingent on 
the initial dose. In the longer term, slow normal tissue 
turnover may allow recovery after low initial doses. This is 
consistent with lack of reported clinical experience of severe 
effects in low dose regions of the central nervous system, 
away from the primary target volume of the initial 
treatment, when compared with fully treated volumes at 
extended re-treatment times.  
Results: The previous work is modified to incorporate the 
above processes to yield estimates for BED2, the %tolerance 
BED after an elapsed time, t, and  BED1, the initial %tolerance 
BED dose. The Probit model is used to extrapolate from 
primate data to the clinical situation, where the incidence of 
myelitis is much lower.  
 
 
The fitted solid curves, with more conservative hatched 
curves, are presented in the Figure, with a superposition of 
both the primate (circles) and rodent data sets (asterisks), 
the latter isoeffective for a 50% incidence of myelitis. This is 
the best available quantitative model, though it must be used 
cautiously in humans where greater longevity and other 
causes for reduced spinal tolerance may concur. So, human 
doses should be below the curves shown. 
A further challenge is to use RBE models to allocate the BEDs 
for charged hadron therapy (protons or ions), which may 
further spare normal tissues and be useful in re-treatments. 
Two examples are given in the table. 
 
 
Conclusions: The new model allows re-treatment dose 
estimation within the time window of 70 days to three years 
after the initial course, and can be adapted for 
hadrontherapy. It should be used cautiously in clinical 
practice by choosing doses lower than predicted. 
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Heating caused by pulsed proton beam energy deposition 
generates a thermoacoustic signal. Based on time-of-flight 
(TOF) calculations, the arrival time of the acoustic waves can 
be used to verify the range of the proton beam(1, 2). The 
goal of this work is to assess the clinical potential of the 
technique by experimentally measuring the acoustic signal 
generated by a proton beam from a hospital-based source 
and to measure the accuracy of the TOF range verification.  
To create a short, intense pulsed proton beam in a hospital 
setting, an electronic function generator was used to 
modulate the IBA C230 isochronous cyclotron at the 
University of Pennsylvania's Roberts Proton Therapy Center. A 
submerged hydrophone measured the acoustic emissions 
generated by the proton beam in water. The acoustic 
measurements were repeated with variable proton current 
and increasing distance between detector and beam. To 
model the expected acoustic signal, simulations were 
performed and compared to experimental results.  
The cyclotron produced proton spills with pulsewidths of 18 
µs and a maximum measured instantaneous proton current of 
790 nA. The collected acoustic signal was on the order of 
mPa, and the pressure amplitude increased monotonically 
with increasing proton current. Based on the observed 
relationship between detector distance and acoustic arrival 
time, the measured signal originated in the proton beam 
dose deposition volume. The acoustic frequency spectrum 
peaked at 10-20 kHz. At a single detector position, the 
arrival time can be measured with a standard deviation of 
0.6 µs (1 mm).  The difference between simulated and 
measured acoustic arrival times has a standard deviation of 
0.9 µs (1.4 mm).  
We report the first observation of acoustic emissions 
generated by a proton beam from a hospital-based clinical 
cyclotron. Based on the methods presented, acoustic-based 
techniques may provide <2 mm (standard deviation) accuracy 
in verification of proton range.  
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Purpose: Scanned ion-beam delivery offers the highest 
conformation of target dose in external beam radiotherapy. 
However, fast and accurate patient-specific quality assurance 
is challenging. The current clinical standard for verification 
of dose distributions with a 2D array of ionization chambers 
(ICs) is slow and not very suitable for dose delivery using 
scanned ion-beams because the response of the ICs is not 
necessarily independent of beam size and position with 
respect to the IC. 
At present, no suitable method for rapid verification of dose 
distributions for scanned ion-beam delivery is commercially 
available.  
 
Figure 1. A. Imaging principle: raw 2D image measured with a 
360 MeV 4He-beam. B. Schematic drawing of the set-up with 
the proton gantry nozzle. 
 
Materials/methods: We are developing a fast QA technique 
based on the UV light produced by swift ions in water 
(Fig.1A). Using fast, UV sensitive CCD cameras we measure 
the light distributions from which the dose distribution is 
reconstructed [2]. The system consist of a water tank in 
which ion beams are stopped and low noise, high sensitive 
CCD cameras (Fig.1B), which register the light distribution 
produced by each of the many subsequent ion beams that 
compose the treatment plan. Data can be taken in two 
modes: integral and differential (synchronized with beam 
delivery), thus allowing the detailed reconstruction of the 
contribution of each individual beam to the dose distribution.  
Results: We have built a prototype optical dose imaging 
system to demonstrate the potential of this method for 3D 
dose scanning in clinical conditions (to verify actual 
treatment plans in particle therapy clinics). We 
demonstrated the feasibility of optical imaging of the full 3D 
dose distribution in water with a small (<1% by weight) 
admixture of a nontoxic , low-cost fluorescent emitting 
visible light. In experiments with 90 MeV proton beams 
approx. 50 photons/MeV were produced in the solution, 
allowing for high quality imaging. Bragg curves measured in 
pure water show a good agreement with those of an 
ionisation chamber, while those measured with the 
fluorescent show some concentration dependent quenching. 
Conclusions: The presented novel method resolves the issues 
of the QA techniques currently used in particle therapy: it 
has high position resolution in three dimensions, features 
direct measurement in the reference material water, and is 
fast as the whole dose distribution is imaged in a single dose 
delivery.  
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Chronic low-dose rate irradiation has been shown to be 
beneficial in a variety of animal models including cancer. To 
assess the specific transcriptional changes that tumor-bearing 
mice would have manifested upon LDR in comparison with 
that of normal mice undergoing LDR irradiation, we 
investigated the expression of DNA repair and damage-
associated genes in the thymus of naturally occurring tumor-
bearing AKR/J and normal ICR mice following low-dose-rate 
(LDR, Cs-137, 0.7 mGy/h, a cumulative dose: 1.7 Gy) 
irradiation. Thymuses were collected at 100th day post 
irradiation and analyzed using whole-genome microarray, 
quantitative reverse transcription polymerase chain (qPCR), 
and western blot. The thymus weight was decreased and 
survival rate was increased in LDR irradiated AKR/J mice 
while no significant changes were found in normal ICR mice. 
qPCR analysis demonstrated Serpina1a, Mmp3, Gzmc, Neil2, 
Plxnc1, Rnd3, Cyp11a1, Ptgs2 were specially altered in LDR-
irradiated AKR/J mice but not in ICR mice. By performing 
Western blot, we found that Plxnc1 and Rnd3, genes involved 
in suppression of melanoma progression, were upregulated 
while Cyp11a1, a gene contributes to tumor immune escape, 
was downregulated in LDR-irradiated AKR/J mice, but not ICR 
mice. These results suggest that LDR γ-radiation suppressed 
early stage of carcinogenesis and removed cancer cells from 
body by stimulating apoptosis and immune-mediated 
mechanisms. Therefore, LDR may offer significant benefit for 
the patients with solid cancer, which has traditionally been 
thought to be a relatively radiotherapy-resistant tumor. 
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Purpose: The accuracy of scanned proton therapy suffers 
from respiratory or cardiac motion during irradiation: The 
discrete scan pattern can interfere with the induced motion 
of the target yielding regions of over- and underdosage [1]. 
Applying the same field multiple times with proportionally 
reduced dose – commonly referred to as rescanning – can 
help averaging out such interferences [2]. However, dead 
